January 05, 2024
A Delaware judge found a gene therapy patent at the center of an infringement suit against Sarepta, brought by the University of Pennsylvania, was ineligible for patent protection because the claims cover a combination of two recombinant DNA sequences that are already naturally occurring.
January 04, 2022
A Delaware federal judge told Massachusetts biotechnology company Sarepta on Tuesday that it could not use the "safe harbor" provisions of the Hatch-Waxman Act to protect a gene therapy it is developing with Roche to treat muscular dystrophy from a patent infringement lawsuit by the University of Pennsylvania.
December 16, 2021
Gilead Sciences will ask a Delaware federal judge next week to block the federal government from deposing the pharmaceutical company's CEO in a high-profile patent case over allegations Gilead made billions by selling HIV medications using research funded by taxpayers. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.